Criteria supporting the study of drugs in the newborn

Clinical Therapeutics

Volumn 28, Issue 9, 2006, Pages 1385-1398

  Ward, Robert M ^a   Benitz, William E ^b   Benjamin Jr , Daniel K ^c   Blackmon, Lillian ^d   Giacoia, George P ^e   Hudak, Mark ^f   Lasky, Tamar ^e   Rodriguez, William ^g   Selen, Arzu ^g  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

drugs prioritization; neonatal therapeutics; newborns; pediatric study

Indexed keywords

ANTICONVULSIVE AGENT; ANTIVIRUS AGENT; BETAMETHASONE; CHLORAMPHENICOL; CISAPRIDE; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCORTISONE; IMIDAZOLE; IMMUNOGLOBULIN; INDOMETACIN; LUNG SURFACTANT; MACROLIDE; MEASLES VACCINE; METHYLXANTHINE; METOCLOPRAMIDE; MORPHINE; PHENOBARBITAL; POLIOMYELITIS VACCINE; PROSTACYCLIN; PROTON PUMP INHIBITOR; RANITIDINE; RETINOL; ROTAVIRUS VACCINE; SPIRONOLACTONE; THEOPHYLLINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

AGE DISTRIBUTION; APNEA; ARTICLE; BIRTH DEFECT; CHOLESTASIS; CHRONIC LUNG DISEASE; CLEFT PALATE; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DIGESTIVE SYSTEM PERFORATION; DIURESIS; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG INDICATION; DRUG INFORMATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GRAY BABY SYNDROME; GROWTH RETARDATION; HEART ARRHYTHMIA; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; HYPOTENSION; INTUSSUSCEPTION; LUNG DYSPLASIA; MEDICAL SOCIETY; NATRIURESIS; NECROTIZING ENTEROCOLITIS; NEUROLOGICAL COMPLICATION; NEWBORN CARE; NONHUMAN; PEDIATRICIAN; PERTUSSIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS SYNDROME; RISK BENEFIT ANALYSIS; SIDE EFFECT; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CONSENSUS DEVELOPMENT CONFERENCES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG EVALUATION; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750039170     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.09.007     Document Type: Article

References (76)

1. Wilson J.T. An update on the therapeutic orphan. Pediatrics 104 (1999) 585-590
2. Accessed August 24, 2006. US Food and Drug Administration. The pediatric exclusivity provision (2001). http://www.fda.gov/cder/pediatric/reportcong0l.pdf Accessed August 24, 2006
3. Available at:. Best Pharmaceuticals for Children Act: 2002. Accessed (August 24, 2006). bin/useftp.cgi?I Paddress=162.140.64.88filename=publ109.107& directory=/diskc/wais/data/107.cong_public_laws
4. List of drugs for which pediatric studies are needed. Federal Register 68 (2003) 2789-2790
5. Burns L.E., Hodgman J.E., and Cass A.B. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med. 261 (1959) 1318-1321
6. Johnson T.N. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 192 (2003) 37-48
7. Andersen D.H., Blanc W.A., Crozier D.N., and Silverman W.A. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18 (1956) 614-625
8. Stewart D.J. The effects of tetracyclines upon the dentition. Br J Dermatol. 76 (1964) 374-378
9. Ayalew K., Nambiar S., Yasinskaya Y., and Jantausch B.A. Carbapenems in pediatrics. Ther Drug Monit. 25 (2003) 593-599
10. Jobe A.H. Pulmonary surfactant therapy. N Engl J Med. 328 (1993) 861-868
11. Adhikari N., Burns K.E., and Meade M.O. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 4 (2004) CD004477
12. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 351 (2004) 1425-1436
13. Konduri G.G. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol. 31 (2004) 591-611
14. discussion S59-S64. Blajchman M.A. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinotysis 5 Suppl 1 (1994) S5-S11
15. Tyson J.E., Wright L.L., Oh W., et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 340 (1999) 1962-1968
16. Levine A., Maayan A., Shamir R., et al. Parenteral nutritionassociated cholestasis in preterm neonates: Evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab. 12 (1999) 549-553
17. Chen C.Y., Tsao P.N., Chen H.L., et al. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. J Pediatr 145 (2004) 317-321
18. Kearns G.L., and Winter H.S. Proton pump inhibitors in pediatrics: Relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr. 37 Suppl 1 (2003) S52-S59
19. Demmler G.J. Congenital cytomegalovirus infection treatment. Pediatr Infect Dis J. 22 (2003) 1005-1006
20. Reyes C., Pereira S., Warden M.J., and Sills J. Cytomegalovirus enteritis in a premature infant. J Pediatr Surg. 32 (1997) 1545-1547
21. Farrell P.M., and Wood R.E. Epidemiology of hyaline membrane disease in the United States: Analysis of national mortality statistics. Pediatrics 58 (1976) 167-176
22. Hamvas A., Wise P.H., Yang R.K., et al. The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites. N Engl J Med. 334 (1996) 1635-1640
23. Dennery P.A., Seidman D.S., and Stevenson D.K. Neonatal hyperbilirubinemia. N Engl J Med. 344 (2001) 581-590
24. Banks B.A., Macones G., Cnaan A., et al. Multiple courses of antenatal corticosteroids are associated with early severe lung disease in preterm neonates. J Perinatol. 22 (2002) 101-107
25. Drummond G.S., and Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc Natl Acad Sci U S A 78 (1981) 6466-6470
26. Kimball A.L., and Carlton D.P. Gastroesophageal reflux medications in the treatment of apnea in premature infants. J Pediatr. 138 (2001) 355-360
27. Musgrove B.S., and Miwa L.J. Excessively thick extemporaneous spironolactone suspension. Am J Hosp Pharm. 46 (1989) 486
28. Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: Associa tion with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 33 (1984) 198-199
29. Anand K.J., Hall R.W., Desai N., et al., NEOPAIN Trial Investigators Group. Effects of morphine anal gesia in ventilated preterm neonates: Primary outcomes from the NEOPAIN randomised trial. Lancet 363 (2004) 1673-1682
30. [published correction appears in Lancet. 2000;355: 758]. Honein M.A., Paulozzi L.J., Himelright I.M., et al. Infantile hypertrophic pyloric stenosis after pertussis prophy laxis with erythromycin: A case review and cohort study. Lancet 354 (1999) 2101-2105
31. Cooper W.O., Griffin M.R., Arbogast P., et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med. 156 (2002) 647-650
32. Hauben M., and Amsden G.W. The association of erythromycin and infantile hypertrophic pyloric stenosis: Causal or coincidental?. Drug Saf. 25 (2002) 929-942
33. [published correction appears in N Engl J Med. 2001;344:1564]. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al., Rotavirus Intussusception Investigation Team. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 344 (2001) 564-572
34. Pearce R.E., Gotschall R.R., Kearns G.L., and Leeder J.S. Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: Differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 29 (2001) 1548-1554
35. Michalets E.L., and Williams C.R. Drug interactions with cisapride: Clinical implications. Clin Pharmacokinet 39 (2000) 49-75
36. Stark A.R., Carlo W.A., Tyson J.E., et al., National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 344 (2001) 95-101
37. Watterberg K.L., Gerdes J.S., Cole C.H., et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: A multicenter trial. Pediatrics 114 (2004) 1649-1657
38. Kuzemko J.A., and Paala J. Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child. 48 (1973) 404-406
39. Lucey J.F. The xanthine treatment of apnea of prematurity. Pediatrics 55 (1975) 584-586
40. Shannon D.C., Gotay F., Stein I.M., et al. Prevention of apnea and bradycardia in low-birthweight infants. Pediatrics 55 (1975) 589-594
41. Uauy R., Shapiro D.L., Smith B., and Warshaw J.B. Treatment of severe apnea in prematures with orally ad ministered theophylline. Pediatrics 55 (1975) 595-598
42. Aranda J.V., and Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol 6 (1979) 87-108
43. Larcher V.F., Gamsu H.R., Sanderson M.C., et al. Theophylline toxicity in a neonate. Arch Dis Child 53 (1978) 757-759
44. Loughran P.M., and McNamara J.M. Paroxysmal supraventricular tachycardia during theophylline therapy in a premature infant. J Pediatr. 92 (1978) 1016-1018
45. Shannon D.C., and Gotay F. Effects of theophylline on serum and urine electrolytes in preterm infants with apnea. J Pediatr. 94 (1979) 963-965
46. Ward R.M. Maternal-placental-fetal unit: Unique problems of pharmacologic study. Pediatr Clin North Am. 36 (1989) 1075-1088
47. Lahti A., Antila E., and Saxen L. The effect of hydrocortisone on the closure of the palatal shelves in two inbred strains of mice in vivo and in vitro. Teratology 6 (1972) 37-41
48. Heinonen O.P., Slone P., and Shapiro S. Hormones, hormone antagonists, and contraceptives. Birth Defects and Drugs in Pregnancy (1982), John Wright-PSG Inc, Boston, Mass 388-400
49. Epstein M.F., Farrell P.M., Sparks J.W., et al. Maternal betamethasone and fetal growth and development in the monkey. Am J Obstet Gynecol 127 (1977) 261-263
50. Cotterrell M., Balazs R., and Johnson A.L. Effects of corticosteroids on the biochemical maturation of rat brain: Postnatal cell form ation. J Neurochem. 19 (1972) 2151-2167
51. Gumbinas M., Oda M., and Huttenlocher P. The effects of corticosteroids on myelination of the developing rat brain. Biol Neonate 22 (1973) 355-366
52. Ballard R.A., and Ballard P.L. Prevention of neonatal respiratory distress syndrome by pharmacological meth ods. In: Robertson B., Van Golde L.M.G., and Batenburg J.J. (Eds). Pulmonary Surfactant: From Molecular Biology to Clinical Practice (1992), Elsevier Science Publishers BV, Amsterdam, The Netherlands 539-560
53. Yeh T.F., Lin Y.J., Huang C.C., et al. Early dexamethasone therapy in preterm infants: A follow-up study. Pediatrics 101 (1998) E7
54. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 350 (2004) 1304-1313
55. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 1 (2003) CDO01146
56. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Moderately early (7-14 days) postnatal corticosteroids for pre venting chronic lung disease in preterm infants. Cochrane Database Syst Rev. 1 (2003) CD001144
57. Halliday H.L., Ehrenkranz R.A., and Doyle L.W. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 1 (2003) CD001145
58. Gordon A., and Isaacs D. Late-onset infection and the role of antibiotic prescribing policies. Curr Opin Infect Dis. 17 (2004) 231-236
59. Choi S.H., Kim Y.S., Chung J.W., et al. Serratia bacteremia in a large university hospital: Trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol. 23 (2002) 740-747
60. Available at:. Department of Health and Human Services. Categories of research that may be reviewed by the institutional review board through an expedited review procedure. Accessed (August 28, 2006). http://www.ihs.gov/MedicalPrograms/Research/pdffiles/expedite.pdf
61. Abstract 1808. Available at:. Heresi G., Gerstmann D., and Blumer J. A pharmacokinetic study of micafungin (FK463) in premature infants. Accessed August 25, 2006. Pediatric Academic Societies Meeting (2003). http://www.abstractview.com/pasall/index.php
62. Peliowski A., and Finer N.N. A blinded, randomized, placebo-controlled trial to compare theophylline and doxa pram for the treatment of apnea of prematurity. J Pediatr 116 (1990) 648-653
63. Fanaroff A.A., Korones S.B., Wright L.L., et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-lowbirth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 330 (1994) 1107-1113
64. Abstract 2232. Available at:. Bloom B., Schelonka R., Keueser T., et al. Multicenter phase II study to assess safety and preliminary efficacy of vero nate, a donor-selected anti-staphylococcal immune globulin in very low birth weight infants. Accessed August 25, 2006. Pediatric Academic Societies Meeting (2004). http://www.abstractview.com/pasall/index.php
65. Abstract 1572. Available at:. Weisman L.E., Fischer G.W., Mandy G.T., et al. Safety and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody in healthy adults. Accessed August 25, 2006. Pediatric Academic Societies Meeting (2002). http://www.abstractview.com/pasall/index.php
66. Abstract 2345. Available at:. Benjamin D.K., Schelonka R., White R., et al. A blinded, randomized, multicenter study to assess the safe ty of an intravenous Staphylococcus aureus immune globulin (human) [Altastaph™] in very-low-birth-weight neonates. Accessed August 25, 2006. Pediatric Academic Societies Meeting (2005). http://www.abstractview.com/pasall/index.php
67. Lam B.C., and Yeung C.Y. Surfactant lavage for meconium aspiration syndrome: A pilot study. Pediatrics 103 (1999) 1014-1018
68. Wiswell T.E., Knight G.R., Finer N.N., et al. A multicenter, randomized, controlled trial comparing surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109 (2002) 1081-1087
69. Notter R.H. Exogenous lung surfactants: Current and future. Lung Surfactants Basic Science and Clinical Applications (2000), Marcel Dekker, Inc, New York, NY 319-345
70. [published correction appears in Lancet. 2000; 356:600]. Ainsworth S.B., Beresford M.W., Milligan D.W., et al. Pumactant and poractant alfa for treatment of res piratory distress syndrome in neonates born at 25-29 weeks' gestation: A randomised trial. Lancet 355 (2000) 1387-1392
71. Horbar J.D., Wright L.L., Soll R.F., et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 123 (1993) 757-766
72. Hudak M.L., Martin D.J., Egan E.A., et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 100 (1997) 39-50
73. Vermont-Oxford Neonatal Network. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 97 (1996) 1-6
74. Sinha S.K., Lacaze-Masmonteil T., Valls i Soler A., et al., Surfaxin Therapy Against Respiratory Dis tress Syndrome Collaborative Group. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115 (2005) 1030-1038
75. Powell J.R., and Donn K.H. The pharmacokinetic basis for H2-antagonist drug interactions: Concepts and im plications. J Clin Gastroenterol 5 Suppl 1 (1983) 95-113
76. Breen K.J., Bury R., Desmond P.V., et al. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin Pharmacol Ther. 31 (1982) 297-300